Memantine for Enhanced Stroke Recovery

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Treatments: Memantine

Criteria

Inclusion Criteria:

1. Age >18 years old

2. Randomization between 3 days-8 weeks days of stroke symptom onset

3. Arm weakness severe enough to warrant inpatient or outpatient occupational therapies

4. Able to voluntarily move affected UE

5. Living independently prior to their stroke

6. Image-confirmed ischemic stroke (MRI or CT)

7. Supratentorial location of stroke

8. Fugl-Meyer Upper Extremity Score of 50 or less and/or Fugl Meyer Lower Extremity Score of 28 or less

9. Ability to swallow pills

Exclusion Criteria:

1. subarachnoid hemorrhage, subdural hemorrhage or other cause of symptoms other than ischemic or hemorrhagic stroke

2. Infratentorial location of stroke (brainstem or cerebellum)

3. NIH Stroke Scale >20 at the time of randomization

4. History of dementia that will interfere with rehabilitation

5. Pre or post-stroke use of memantine or amantadine

6. Contraindications to taking memantine XR in pill form

7. History of prior clinical stroke with residual symptoms on the same side as the current symptoms that would interfere with outcomes of this study

8. Documented severe renal impairment (CrCl < 30 ml/min) Blood tests will be performed prior to study procedures that will ensure patients do not have renal impairment if not done as part of clinical care.

9. Moribund or not expected to live 6 months

10. Severe cognitive deficits or pre-morbid function causing inaccurate neurologic assessment or inability to complete the initial assessment

11. Comorbid neurologic disease that would interfere with the results including but not limited to Multiple Sclerosis, neurodegenerative diseases, spinal cord disease, and central nervous system cancer.

12. Documented severe hepatic impairment (Child-Pugh score > 6) or severe hepatic disease (hepatitis)

13. Patients who are pregnant or breast feeding